发明授权
US08362072B2 BRCA1-based breast or ovarian cancer treatment agents and methods of use
失效
基于BRCA1的乳腺癌或卵巢癌治疗剂及其使用方法
- 专利标题： BRCA1-based breast or ovarian cancer treatment agents and methods of use
- 专利标题（中）： 基于BRCA1的乳腺癌或卵巢癌治疗剂及其使用方法
-
申请号： US13525831申请日： 2012-06-18
-
公开(公告)号： US08362072B2公开(公告)日： 2013-01-29
- 发明人: Roy A. Jensen , Lisa M. Harlan-Williams , Frank J. Schoenen , Jeffrey Aube , Gerald H. Lushington
- 申请人： Roy A. Jensen , Lisa M. Harlan-Williams , Frank J. Schoenen , Jeffrey Aube , Gerald H. Lushington
- 申请人地址： US KS Lawrence
- 专利权人： University of Kansas
- 当前专利权人： University of Kansas
- 当前专利权人地址： US KS Lawrence
- 代理机构： Licata & Tyrrell P.C.
- 主分类号： A61K31/34
- IPC分类号： A61K31/34
摘要：
A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.